Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01781429 · ClinicalTrials.gov registry record · Phase 1

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

A Phase 1 study of Advanced Solid Tumors, sponsored by BioMed Valley Discoveries.

Completed
Registry status
Phase 1
Development phase
136
Enrollment target
9
Study locations

NCT01781429 is a Phase 1 study of Advanced Solid Tumors that has completed, run by BioMed Valley Discoveries. The registered enrollment target is 136 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (31% lower). The trial reports 9 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01781429, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by BioMed Valley Discoveries.

COMPLETED
Registry status
Phase 1
Development phase
136 participants
Enrollment target
9
Study locations

Study Summary

This open-label, multi-center Phase 1/2 study will assess the safety, pharmacokinetics, and pharmacodynamics of escalating doses of BVD-523 in patients with advanced malignancies. The study also seeks to demonstrate target modulation and early signs of clinical response in select patient populations.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG BVD-523

Study Locations (9)

Tennessee

  • Sarah Cannon Research Institute Hospital at Vanderbilt - Nashville
  • Vanderbilt-Ingram Cancer Center - Nashville

California

  • UCLA Med-Hematology & Oncology - Los Angeles

Connecticut

  • Yale Cancer Center - New Haven

Florida

  • Florida Cancer Specialists and Research Group (Sarah Cannon Research Institute) - Sarasota

Massachusetts

  • Massachusetts General Hospital (MGH) - Boston

Missouri

  • Washington University School of Medicine - St Louis

New York

  • Memorial Sloan-Kettering Cancer Center - New York

Texas

  • UT M.D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 136 participants
Start Date 2013-03
Est. Completion 2018-09
Phase Phase 1

Sponsor

BioMed Valley Discoveries

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01781429

The ClinicalTrials.gov registry entry for NCT01781429 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (31% lower). The listed sponsor is BioMed Valley Discoveries, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which BVD-523 is the first listed.

NCT01781429 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Tennessee, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT01781429 about?

NCT01781429 is a clinical study titled "Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies". This open-label, multi-center Phase 1/2 study will assess the safety, pharmacokinetics, and pharmacodynamics of escalating doses of BVD-523 in patients with advanced malignancies. The study also seeks to demonstrate target modulation and early signs of clinical response in select patient populations...

What is the current status of trial NCT01781429?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 136 participants. The study started on 2013-03. Estimated completion is 2018-09.

What conditions does trial NCT01781429 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT01781429?

The interventions under investigation include: BVD-523 (DRUG).

Who is sponsoring clinical trial NCT01781429?

This trial is sponsored by BioMed Valley Discoveries, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01781429 being conducted?

This trial has 9 study locations across California, Connecticut, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.